Antibody Details
Product Details
ImmunogenGST fusion protein expressed in E. coli corresponding to aa 341-748 of full-length BRCA1. Product PreparationPurified by Protein G affinity chromatography Storage and HandlingThis antibody is stable for at least one (1) year at -70°C. Avoid multiple freeze- thaw cycles. Regulatory StatusResearch Use Only Applications and Recommended Usage? Quality Tested by LeincoImmunoblotting: use at 1-10 ug/mL.
Immunoprecipitation: use at 1-10 ug/mL.
Positive controls: Any normal human tissue, especially those containing rapidly proliferating cells, such as lymphoid germinal centers. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. Description
SpecificityThis antibody recognizes full-length BRCA1, a 220 kD nuclear phosphoprotein. In a high proportion of breast and ovarian cancer cell lines, BRCA1 aberrantly mislocates to the cytoplasm. Its usefulness to monitor functional inactivation of BRCA1 in sporadic breast cancers is under active investigation. FunctionE3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage (PubMed:12890688, PubMed:14976165, PubMed:16818604, PubMed:17525340, PubMed:12887909, PubMed:10500182, PubMed:19261748). It is unclear whether it also mediates the formation of other types of polyubiquitin chains (PubMed:12890688). The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability (PubMed:12890688, PubMed:14976165, PubMed:20351172). Regulates centrosomal microtubule nucleation (PubMed:18056443). Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle (PubMed:10724175, PubMed:12183412, PubMed:11836499, PubMed:19261748). Required for FANCD2 targeting to sites of DNA damage (PubMed:12887909). Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation (PubMed:16326698). Contributes to homologous rPubMed:10500182, PubMed:10724175, PubMed:11836499, PubMed:12183412, PubMed:12887909, PubMed:12890688, PubMed:14976165, PubMed:16326698, PubMed:16818604, PubMed:17525340, PubMed:18056443, PubMed:19261748, PubMed:19369211, PubMed:20160719, PubMed:20351172}. References & Citations
Chen, Y et al. (1995) Science 270: 789- 791 Chen, C-F et al. (1995) J Biol Chem 271: 32863-32868 Chen, Y et al. (1996) Cancer Res 56: 3168-3172.
ICC IF Chromatin IP (ChIP) IHC-P
Certificate of Analysis
|